3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Renal Cell
64
Neoplasm Metastasis
25
Kidney Neoplasms
21
Neoplasms
16
Breast Neoplasms
15
Carcinoma, Non-Small-Cell Lung
13
Urinary Bladder Neoplasms
12
Prostatic Neoplasms
10
Lung Neoplasms
8
Brain Neoplasms
8
Melanoma
7
Colorectal Neoplasms
7
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Neuroendocrine Tumors
6
Liver Neoplasms
6
Glioblastoma
6
Gastrointestinal Stromal Tumors
6
Carcinoma, Hepatocellular
6
Thyroid Neoplasms
5
Thymoma
5
Small Cell Lung Carcinoma
5
Recurrence
5
Multiple Myeloma
5
Esophageal Neoplasms
5
Carcinoma
5
Uveal Melanoma
4
Stomach Neoplasms
4
Sarcoma
4
Adenocarcinoma
4
Interventions
atezolizumab
2
Sorafenib
2
Bevacizumab
2
titanium silicide
1
ledipasvir, sofosbuvir drug combination
1
halofantrine
1
genexol-PM
1
durvalumab
1
avatrombopag
1
aumolertinib
1
Sunitinib
1
Ramucirumab
1
Neoadjuvant Therapy
1
N-monoacetylcystine
1
Leucovorin
1
Injections
1
Immunotherapy
1
Formyltetrahydrofolates
1
Everolimus
1
Cisplatin
1
Catheter Ablation
1
Adjuvants, Pharmaceutic
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Liver Diseases
×
Sunitinib
×
Clear all
NCT01215565
2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
4 enrolled